Thomas C. Hohman

Director/Miembro de la Junta en Ocugenix Corp. .

Health Services

Perfil

Thomas C.
Hohman is currently a Director at Ocugenix Corp.
and Galimedix Therapeutics, Inc. There is no additional information provided about his career history.

Cargos activos de Thomas C. Hohman

Empresas	Cargo	Inicio
Ocugenix Corp. Ocugenix Corp. Medical/Nursing ServicesHealth Services Ocugenix Corp. operates as a therapeutics company focusing on he development of of cancer immunotherapy drug for eye diseases. The company is headquartered in Pittsburgh, PA.	Director/Miembro de la Junta	-
Galimedix Therapeutics, Inc. (Maryland) Galimedix Therapeutics, Inc. (Maryland) Medical/Nursing ServicesHealth Services Galimedix Therapeutics, Inc. is an ophthalmic pharmaceutical company based in Kensington, MD. Galimedix is focused on developing innovative treatments for various neurodegenerative diseases. The company's lead product, GAL-101, has shown promising results in treating these diseases. The company was founded by Chris Parsons, Andrew Leonard Pearlman, Alexander Gebauer.	Director/Miembro de la Junta	-

Todos los cargos activos de Thomas C. Hohman

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Thomas C. Hohman.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Ocugenix Corp. Ocugenix Corp. Medical/Nursing ServicesHealth Services Ocugenix Corp. operates as a therapeutics company focusing on he development of of cancer immunotherapy drug for eye diseases. The company is headquartered in Pittsburgh, PA.	Health Services
Galimedix Therapeutics, Inc. (Maryland) Galimedix Therapeutics, Inc. (Maryland) Medical/Nursing ServicesHealth Services Galimedix Therapeutics, Inc. is an ophthalmic pharmaceutical company based in Kensington, MD. Galimedix is focused on developing innovative treatments for various neurodegenerative diseases. The company's lead product, GAL-101, has shown promising results in treating these diseases. The company was founded by Chris Parsons, Andrew Leonard Pearlman, Alexander Gebauer.	Health Services